Long-term androgen deprivation, with or without radiotherapy, in locally-advanced prostate cancer: updated results from a phase III randomized trial.
We previously reported results of a randomized trial comparing androgen-deprivation therapy (ADT) combined with external beam radiation therapy (EBRT) and ADT alone in patients treated with locally advanced prostate cancer. We report here long-term oncological outcomes. In this multicenter phase III trial, patients were randomly assigned to ADT alone or ADT+EBRT. Leuprorelin 11.25 mg was administered for three years. The whole pelvis was treated at a dose of 46Gy and the prostate with a boost from 20Gy to 28Gy. Primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), disease-specific survival (DSS), locoregional progression free survival (LPFS), metastasis-free survival (MFS), biochemical progression free survival (BPFS) and tolerance. With a median follow-up of 7.3 years, 263 patients were included. The 8-year PFS rate was significantly higher in the ADT+EBRT arm than in the ADT arm (48% versus 7%; hazard ratio: 0.27; 95%CI: (0.17;0.39), p<0.0001) (hazard ratio [HR] = 0.10; 95%CI: (0.05; 0.20); p < 0.0001 in patients with baseline PSA ≥ 50ng/ml and HR = 0.28; 95%CI: (0.19; 0.40), p < 0.0001 in patients with baseline PSA < 50ng/ml). The risk of death from prostate cancer was significantly reduced for ADT+EBRT arm (sub-hazard ratio (SHR): 0.48; 95%CI: (0.25; 0.91); p=0.02). The 8-year OS rate was respectively 57% in the ADT arm and 65% in the ADT+EBRT arm (no significant difference). LPFS was significantly in favor of ADT+EBRT arm (SHR = 0.61; 95%CI: (0.42; 0.89); p=0.01). MFS was comparable between both arms (p=0.88). Analysis of toxicities revealed acute lower tolerance in the ADT+EBRT arm with a gradual decrease in intensity from 6 months after the end of EBRT. These long-term results confirm the oncological benefit of combining EBRT with ADT in the treatment of locally advanced prostate cancer. This article is protected by copyright. All rights reserved.